PURPOSE: To perform aggressive radiotherapy for vertebral metastases. Using very steep dose gradients from intensity-modulated radiotherapy (IMRT), a protocol based on the concept of partial volume dose to the spinal cord was evaluated. PATIENTS AND METHODS: 50 patients with vertebral metastases were treated using IMRT. In previously unirradiated cases, where a prescribed dose of 80 Gy (BED10) was delivered, the constraint to the spinal cord should be less than 100 Gy (BED2). For previously irradiated cases, on the other hand, the dose is the same as in the previously unirradiated case; however, constraints for the spinal cord are a cumulative BED2 of less than 150 Gy, BED2 of less than 100 Gy in each instance, and a treatment gap of more than 6 months. There were 6 patients considered for a partial volume dose to the spinal cord. They all received higher BED2, ranging from 51-157 Gy of D1cc. RESULTS: Among the 24 patients who survived longer than 1 year, there was 1 case of transient radiation myelitis. There were no other cases of spinal cord sequelae. CONCLUSION: Based on the present results, we recommend a BED2 of 100 Gy or less at D1cc as a constraint for the spinal cord in previously unirradiated cases, and a cumulative BED2 of 150 Gy or less at D1cc in previously irradiated cases, when the interval was not shorter than 6 months and the BED2 for each session was 100 Gy or less. The prescribed BED10 of 80 Gy could be safely delivered to the vertebral lesions.
PURPOSE: To perform aggressive radiotherapy for vertebral metastases. Using very steep dose gradients from intensity-modulated radiotherapy (IMRT), a protocol based on the concept of partial volume dose to the spinal cord was evaluated. PATIENTS AND METHODS: 50 patients with vertebral metastases were treated using IMRT. In previously unirradiated cases, where a prescribed dose of 80 Gy (BED10) was delivered, the constraint to the spinal cord should be less than 100 Gy (BED2). For previously irradiated cases, on the other hand, the dose is the same as in the previously unirradiated case; however, constraints for the spinal cord are a cumulative BED2 of less than 150 Gy, BED2 of less than 100 Gy in each instance, and a treatment gap of more than 6 months. There were 6 patients considered for a partial volume dose to the spinal cord. They all received higher BED2, ranging from 51-157 Gy of D1cc. RESULTS: Among the 24 patients who survived longer than 1 year, there was 1 case of transient radiation myelitis. There were no other cases of spinal cord sequelae. CONCLUSION: Based on the present results, we recommend a BED2 of 100 Gy or less at D1cc as a constraint for the spinal cord in previously unirradiated cases, and a cumulative BED2 of 150 Gy or less at D1cc in previously irradiated cases, when the interval was not shorter than 6 months and the BED2 for each session was 100 Gy or less. The prescribed BED10 of 80 Gy could be safely delivered to the vertebral lesions.
Authors: Wilbert B van den Hout; Yvette M van der Linden; Elsbeth Steenland; Ruud G J Wiggenraad; Job Kievit; Hanneke de Haes; Jan Willem H Leer Journal: J Natl Cancer Inst Date: 2003-02-05 Impact factor: 13.506
Authors: O M Salazar; T Sandhu; N W da Motta; M A Escutia ; E Lanzós-Gonzales; A Mouelle-Sone; A Moscol; M Zaharia; S Zaman Journal: Int J Radiat Oncol Biol Phys Date: 2001-07-01 Impact factor: 7.038
Authors: E Chow; C Danjoux; R Wong; E Szumacher; E Franssen; K Fung; J Finkelstein; L Andersson; R Connolly Journal: Radiother Oncol Date: 2000-09 Impact factor: 6.280
Authors: Samuel Ryu; Jian-Yue Jin; Ryan Jin; Jack Rock; Munther Ajlouni; Benjamin Movsas; Mark Rosenblum; Jae Ho Kim Journal: Cancer Date: 2007-02-01 Impact factor: 6.860
Authors: Johanna Meisner; Andreas Meyer; Bernd Polivka; Johann H Karstens; Michael Bremer Journal: Strahlenther Onkol Date: 2010-01-26 Impact factor: 3.621
Authors: Carsten Nieder; Anca L Grosu; Nicolaus H Andratschke; Michael Molls Journal: Int J Radiat Oncol Biol Phys Date: 2006-11-02 Impact factor: 7.038
Authors: A T Porter; A J McEwan; J E Powe; R Reid; D G McGowan; H Lukka; J R Sathyanarayana; V N Yakemchuk; G M Thomas; L E Erlich Journal: Int J Radiat Oncol Biol Phys Date: 1993-04-02 Impact factor: 7.038
Authors: S Lorentini; M Amichetti; L Spiazzi; S Tonoli; S M Magrini; F Fellin; M Schwarz Journal: Strahlenther Onkol Date: 2012-02-10 Impact factor: 3.621
Authors: D Rades; S Douglas; T Veninga; A Bajrovic; L J A Stalpers; P J Hoskin; V Rudat; S E Schild Journal: Strahlenther Onkol Date: 2012-02-25 Impact factor: 3.621
Authors: D Rades; S Huttenlocher; J N Evers; A Bajrovic; J H Karstens; V Rudat; S E Schild Journal: Strahlenther Onkol Date: 2012-02-16 Impact factor: 3.621
Authors: V E M Mul; J M A de Jong; L H P Murrer; P L A van den Ende; R M A Houben; M Lacko; P Lambin; B G Baumert Journal: Strahlenther Onkol Date: 2011-12-23 Impact factor: 3.621
Authors: D Rades; S Douglas; T Veninga; P Poortmans; A Bajrovic; P J Hoskin; V Rudat; S E Schild Journal: Strahlenther Onkol Date: 2012-03-14 Impact factor: 3.621
Authors: D Rades; S Douglas; T Veninga; A Bajrovic; L J A Stalpers; P J Hoskin; V Rudat; S E Schild Journal: Strahlenther Onkol Date: 2012-04-25 Impact factor: 3.621